Esperion Therapeutics Inc banner

Esperion Therapeutics Inc
NASDAQ:ESPR

Watchlist Manager
Esperion Therapeutics Inc Logo
Esperion Therapeutics Inc
NASDAQ:ESPR
Watchlist
Price: 2.05 USD -5.53% Market Closed
Market Cap: $526.5m

During the last 3 months Esperion Therapeutics Inc insiders have not bought any shares, and sold 107.2k USD worth of shares. The stock price has dropped by 29% over this period (open performance analysis).

The last transaction was made on Mar 17, 2026 by Koenig Sheldon L. , who sold 69.5k USD worth of ESPR shares.

Last Transactions:
Halladay Benjamin
$-17.4k
Looker Benjamin
$-15.4k
Koenig Sheldon L.
$-69.5k
Looker Benjamin
$-4.9k
Koenig Sheldon L.
$-177.2k
Halladay Benjamin
$-26.9k
Looker Benjamin
$-23.9k
Looker Benjamin
$-3.3k
Halladay Benjamin
$-19.8k
Looker Benjamin
$-17.6k
Koenig Sheldon L.
$-79.3k
Halladay Benjamin
$-12.3
Looker Benjamin
$-1.5k
Looker Benjamin
$-7.4k
Koenig Sheldon L.
$-33.8k
Halladay Benjamin
$-8.3k
Warren Eric
$-105.6
Halladay Benjamin
$-7.7
Halladay Benjamin
$-5.2k
Warren Eric
$-3.6k
Koenig Sheldon L.
$-19.6k
Halladay Benjamin
$-20.5
Warren Eric
$-446.5
Halladay Benjamin
$-20.4
Warren Eric
$-278
Koenig Sheldon L.
$-30.7k
Warren Eric
$-5.4k
Halladay Benjamin
$-7.9k
Warren Eric
$-426.5
Warren Eric
$-226.7
Warren Eric
$-4.7k
Koenig Sheldon L.
$-26.1k
View All Transactions

During the last 3 months Esperion Therapeutics Inc insiders have not bought any shares, and sold 107.2k USD worth of shares. The stock price has dropped by 29% over this period (open performance analysis).

The last transaction was made on Mar 17, 2026 by Koenig Sheldon L. , who sold 69.5k USD worth of ESPR shares.

Sold
0-3
months
107.2k USD
3
3-6
months
228k USD
3
6-9
months
119.9k USD
3
9-12
months
51k USD
3
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Esperion Therapeutics Inc
Insider Trading Chart

Esperion Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Esperion Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Esperion Therapeutics Inc
Glance View

Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

ESPR Intrinsic Value
LOCKED
Unlock

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett